Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

N99-02: Melphalan and Buthionine Sulfoximine (BSO)

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
New Approaches to Neuroblastoma Therapy Consortium
ClinicalTrials.gov Identifier:
NCT00005835
First received: June 2, 2000
Last updated: August 27, 2016
Last verified: June 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2016
  Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)